Denosumab is superior to alendronate for improving cortical bone porosity post-menopause
How to Cite
OrthoEvidence. Denosumab is superior to alendronate for improving cortical bone porosity post-menopause. ACE Report. 2014;3(6):6. Available from: https://myorthoevidene.com/AceReport/Report/6038
Differing effects of denosumab and alendronate on cortical and trabecular boneBone. 2014 Feb;59:173-9. doi: 10.1016/j.bone.2013.11.016. Epub 2013 Nov 22.
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Two hundred and forty-seven post-menopausal women (146 with data at final follow-up) received a subcutaneous injection every 6 months and a pill weekly. These treatments were randomized as follows: Group one received denosumab injections and a placebo pill, Group two received alendronate and a placebo injection and Group three received a placebo injection and pill. The purpose of this trial wa...
Continuing Medical Education Credits
You could be earning 0.5 CME credits for each report you read.LEARN MORE